PHOO Stock Overview
Engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Photocure ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 57.70 |
| 52 Week High | NOK 57.70 |
| 52 Week Low | NOK 56.70 |
| Beta | 0.66 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -38.16% |
| 5 Year Change | 22.12% |
| Change since IPO | 70.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHOO | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 0.4% |
| 1Y | n/a | -4.4% | 3.3% |
Return vs Industry: Insufficient data to determine how PHOO performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how PHOO performed against the UK Market.
Price Volatility
| PHOO volatility | |
|---|---|
| PHOO Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: PHOO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHOO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 88 | Dan Schneider | www.photocure.com |
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix.
Photocure ASA Fundamentals Summary
| PHOO fundamental statistics | |
|---|---|
| Market cap | NOK 1.79b |
| Earnings (TTM) | -NOK 33.69m |
| Revenue (TTM) | NOK 462.30m |
3.9x
P/S Ratio-53.3x
P/E RatioIs PHOO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHOO income statement (TTM) | |
|---|---|
| Revenue | NOK 462.30m |
| Cost of Revenue | NOK 25.87m |
| Gross Profit | NOK 436.44m |
| Other Expenses | NOK 470.13m |
| Earnings | -NOK 33.69m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | 94.41% |
| Net Profit Margin | -7.29% |
| Debt/Equity Ratio | 0% |
How did PHOO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/19 13:52 |
| End of Day Share Price | 2023/09/21 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Photocure ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hans Bohn | Beringer Finance AB |
| null null | Brookline Capital Markets |
| Patrik Ling | DNB Markets |